Strengthening the credibility of this conclusion, analysis of the survival statistics of 136 patients who underwent postoperative radiotherapy and chemotherapy also indicated that low expression of SMARCC2 was associated with poor prognosis of glioma (Fig. 1C). The gene discussed is SMARCC2; the disease is central nervous system cancer.